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Abstract
Background: Lymphatic Filariasis (LF) is an important Neglected Tropical Disease, being a major
cause of disability worldwide. The Global Programme to Eliminate Lymphatic Filariasis aims to
eliminate LF as a public health problem by the year 2020, primarily through repeated Mass Drug
Administration (MDA). The Pacific region programme commenced in 1999. By June 2007, five of
the eleven countries classified as endemic had completed five MDA campaigns and post-MDA
prevalence surveys to assess their progress. We review available programme data and discuss their
implications for other LF elimination programs in developing countries.
Methods: Reported MDA coverage and results from initial surveys and post-MDA surveys of LF
using the immunochromatographic test (ICT) from these five Pacific Island countries (Tonga, Niue,
Vanuatu, Samoa and Cook Islands) were analysed to provide an understanding of their quality and
programme progress towards LF elimination. Denominator data reported by each country
programme for 2001 was compared to official sources to assess the accuracy of MDA coverage
data.
Results: Initial survey results from these five countries revealed an ICT prevalence of between 2.7
and 8.6 percent in individuals tested prior to commencement of the programme. Country MDA
coverage results varied depending on the source of denominator data. Of the five countries in this
case study, three countries (Tonga, Niue and Vanuatu) reached the target prevalence of <1%
a n t i g e n a e m i a  f o l l o w i n g  f i v e  r o u n d s  o f  M D A .  However, endpoint data could not be reliably
compared to baseline data as survey methodology varied.
Conclusion: Accurate and representative baseline and post-campaign prevalence data is crucial
for determining program effectiveness and the factors contributing to effectiveness. This is
emphasised by the findings of this case study. While three of the five Pacific countries reported
achieving the target prevalence of <1% antigenaemia, limitations in the data preclude identification
of key determinants of this achievement.
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Background
Lymphatic filariasis (LF), an infection caused by a mos-
quito borne parasite, is the second leading cause of disa-
bility worldwide, affecting more than 120 million people
in 80 countries [1-3]. It is a major cause of physical and
emotional suffering, as well as economic loss [4,5]. The
three species of nematode worm that cause LF are
Wuchereria bancrofti, Brugia malayi and Brugia timori [6].
Bancroftian filariasis accounts for 90% of cases worldwide
[6], including all cases of LF in the Pacific [2].
In 1997 the World Health Organization (WHO) declared
LF one of six potentially eradicable diseases [2]. Subse-
quently, the Global Programme to Eliminate Lymphatic
Filariasis was established to eliminate LF as a public
health problem by the year 2020. The principal strategy
used to accomplish this is mass drug administration
(MDA), which for most countries means administering a
single dose of two drugs (albendazole and diethyl-car-
bamazine or albendazole and ivermectin) to ≥80% of the
entire "at risk" population annually for four to six years
[6,7]. Field experience suggests that this strategy will
reduce microfilaraemia within the community to very low
levels, potentially resulting in permanent interruption of
transmission [6]. Follow-up surveys are the principle sur-
veillance mechanism employed to assess the effectiveness
of the MDA in decreasing the prevalence of LF in affected
populations.
Historically, levels of filariasis and elephantiasis in the
Pacific region were some of the highest documented in
the world [2]. The Pacific region also has a long history of
efforts to control filariasis; however, such efforts have
been met with varying success. Some countries such as
Wallis and Futuna had persistent and successful elimina-
tion programs for decades, whilst many others have expe-
rienced resurgence after reducing microfilaria prevalence
to levels below 1% [2].
The Pacific Programme to Eliminate Lymphatic Filariasis
was launched in 1999, under the auspices of the World
Health Organization (WHO). During the past seven years
most Pacific Island Countries and Territories (PICTs) have
completed initial surveys to map the extent of LF infec-
tion. Of the 22 PICTs, 11 were found to be endemic for LF.
All endemic countries have commenced MDA with die-
thyl-carbamazine (DEC) and albendazole, targeting their
whole populations, as all people in endemic countries are
considered to be "at risk". Five additional countries had
evidence of limited focal LF activity and three imple-
mented localised treatment interventions. The principal
diagnostic tool used in the Pacific is the immunochroma-
tographic test (ICT), a simple card test with a high
reported sensitivity and specificity, that measures the pres-
ence of W. bancrofti antigen in peripheral blood [8,9].
By June 2007, five PICTs Cook Islands, Niue, Samoa,
Tonga and Vanuatu, had completed five rounds of MDA
and a post-MDA survey using a stratified cluster sample
design to determine the effectiveness of their MDA pro-
gram in reaching the goal of <1% antigenaemia preva-
lence (Figure 1) [2].
The data from these five countries provide an opportunity
to reflect on the progress of the Pacific Programme to date
and provide information for planning future program
activities. Lessons from the Pacific experience highlight
some important issues that may be relevant to other LF
elimination programs around the world.
Methods
Data were collected at country level during the delivery of
each country's LF elimination program and reported to
the WHO to permit collation of country and regional
data. Reports included the number of people participating
in each round of MDA and the results of the pre- and post-
MDA prevalence surveys. It is important to note that
regions within countries adopted different approaches to
drug distribution using both a central distribution point
and less commonly door to door delivery but this was not
systematically recorded.
At the commencement of the Pacific Programme to Elim-
inate Lymphatic Filariasis, each country performed an ini-
tial survey to estimate LF antigenaemia prevalence. All
countries except Niue reported using convenience sampling
for these surveys, while Niue tested all residents. Estimates
of LF antigenaemia prevalence were made from these sur-
veys using ICT, calculated as the number of ICT positive
individuals divided by the number of individuals on
whom ICT tests were performed. This was expressed as a
percentage and entered onto a spreadsheet, using Micro-
soft Excel (Microsoft Office XP Professional version).
Confidence intervals were not calculated for initial sur-
veys due to the use of convenience sampling.
Each country provided their estimated MDA coverage to
the WHO as raw data and percentages of the whole popu-
lation. This was calculated using the treated population,
defined as the number of people provided with medica-
tion, divided by the population that was reported by the
country's LF program as their total population for each
year. This was expressed as a percentage and entered into
a Microsoft Excel spreadsheet.
To determine the accuracy of the reported population data
for each country, the reported population for each year
was compared to other available official sources. To allow
comparison across countries, the data for 2001 is pre-
sented, the year that three of the five countries conducted
a census. Using the population figure supplied by officialBMC Infectious Diseases 2009, 9:92 http://www.biomedcentral.com/1471-2334/9/92
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Government sources from each country, the MDA cover-
age was recalculated and compared to the reported MDA
coverage.
At the completion of five rounds of MDA, four of the case
study countries (Cook Islands, Samoa, Tonga and Van-
uatu) performed a post-MDA prevalence survey using a
stratified cluster sampling design to determine if the target
of <1% prevalence by ICT had been attained. Stratified
cluster sampling was performed by dividing each country
into a number of implementation units, with the proba-
bility of towns and villages based on population size and
geographic location. Within each unit, a random sample
of villages was selected and all eligible residents of these
villages were encouraged to be tested.
Post-MDA prevalence data was calculated as the number
of ICT positive individuals divided by the number of indi-
viduals on whom ICT tests were performed. A 95% confi-
dence interval was calculated for all countries other than
Niue using the Binomial Stats program, "JavaStat" [10].
Between 1999 and 2004, in contrast to the other countries
included in this paper, Niue performed three whole popu-
lation prevalence surveys using ICT. Prevalence was calcu-
lated as previously described.
The collection and analysis of data was undertaken as part
of routine program activities for the Pacific Programme to
Eliminate Lymphatic Filariasis and ethical approval was
not required.
Results
Initial survey results revealed an ICT prevalence of less
than 10% in all five countries, ranging from 8.6% in the
Cook Islands to 2.7% in Tonga (Figure 2). The survey
methodology was not standardised for Tonga, Samoa,
Cook Islands and Vanuatu, and simply described as "con-
venience sampling".
MDA coverage, as reported by each country during the five
rounds of MDA varied from 57–99% (Table 1).
Map of the Pacific Region, highlighting case study countries Figure 1
Map of the Pacific Region, highlighting case study countries.BMC Infectious Diseases 2009, 9:92 http://www.biomedcentral.com/1471-2334/9/92
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For all countries except the Cook Islands, the MDA cover-
age rate decreased when population totals from official
population statistics were used. For example for 2001, a
year in which each of the case study countries conducted
a census, the comparable MDA coverage using LF program
reported population denominators compared to official
government statistics, respectively, were: Cook Islands –
64% vs. 77%; Niue – 99% vs. 95%; Samoa – 68% vs. 67%;
Tonga – 79% vs. 77%; and Vanuatu – 84% vs. 80%).
The baseline and post-MDA ICT prevalence rates reported
by the countries were: Cook Islands 8.6% (162 of 1884
positive) in 1999 to 1.3% (33 of 2202 positive) in 2005;
Niue 3.1% (56 of 1794 positive) in 1999 to 0.2% (3 of
1285 positive) in 2004; Samoa 4.5% (317 of 7006 posi-
tive) in 1999 to 1.1% (48 of 12719 positive) in 2004;
Tonga 2.7% (108 of 4002 positive) in 1999/2000 to 0.4%
(11 of 2927 positive) in 2006; and Vanuatu 4.8% (209 of
4362 positive) in 1998 to 0.2% (18 of 7576 positive) in
2005 (Figure 2).
In Niue three cross-sectional population surveys were
conducted. Niue reported an initial prevalence of 3.1% by
ICT (56/1794). After two and five rounds of MDA, preva-
lence dropped to 1.5% (22/1630) in 2001 and subse-
quently to 0.2% (3/1285) in 2004.
Discussion
Niue provides a unique case study because reliable cross-
sectional population data was available. Niue results indi-
cate that five rounds of MDA with coverage between 78–
99% can decrease ICT prevalence from 3.1% to 0.2%. This
finding supports the premise of the WHO-recommended
strategy, that four to six rounds of MDA with high popu-
lation coverage (≥80%), will successfully reduce the prev-
alence of LF infections to a level where interruption of
transmission is believed to occur [7].
Mathematical modelling by Michael et al (2000) has pre-
dicted that post-MDA LF prevalence will be influenced by
higher LF prevalence at baseline, high MDA coverage and
the use of vector control measures [11]. Unfortunately,
inaccurate initial prevalence data preclude exact determi-
nation of the change in prevalence for these case study
countries, other than Niue. A relatively low initial preva-
lence (3.1%) and high MDA coverage in Niue (>80% cov-
erage in four MDA rounds) may have contributed to the
progress seen in this country.
Niue, Tonga and Vanuatu attained the Pacific Pro-
gramme's target of an ICT positive prevalence of <1% fol-
lowing five rounds of MDA. The remaining two countries
(Cook Islands and Samoa) closely approached but failed
to achieve that target. As a result both countries conducted
an additional MDA round in 2006, with Cook Islands
achieving 94% coverage and Samoa, 93% coverage.
Local vector species and control strategies differ between
the case study countries. For these PICTs, the predomi-
nant vector species are Aedes polynesiensis (Cook Islands,
Samoa), Ae. cooki (Niue), Ae. tabu (Tonga), Ae. oceanicus
(Samoa, Tonga) and Anopheles farauti (Vanuatu) [12]. In
addition, Samoa has Ae. samoanus, Ae. tutuilae and Ae. upo-
lensis, while Tonga has Ae. tongae [12]. It is of interest that
the main LF vector in the two countries with the highest
post-MDA survey results (Samoa and Cook Islands) is Ae.
polynesiensis. This mosquito species is of particular con-
cern in the Pacific region, as there are currently no effec-
tive measures of control and it exhibits a trait called
"limitation", meaning the mosquito becomes more effi-
cient at transmitting LF when the prevalence within the
population is low [12]. The relative contribution of the
presence of this vector species, baseline LF antigenaemia
Lymphatic filariasis antigenaemia prevalence in Pacific case  study countries, baseline and post-MDA surveys Vertical bars represent 95% confidence intervals   *Surveys in Niue were cross-sectional including all available  and eligible residents Figure 2
Lymphatic filariasis antigenaemia prevalence in 
Pacific case study countries, baseline and post-MDA 
surveys.
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Table 1: Mass Drug Administration (MDA) coverage reported by 
country LF programmes
Reported MDA coverage of population (%)
COUNTRY 1st MDA 2nd MDA 3rd MDA 4th MDA 5th MDA
Cook Islands 62 64 98 88 93
Niue 94 99 82 78 85
Samoa 90 57 68 60 80
Tonga 79 84 91 86 85
Vanuatu 83 84 84 87 85BMC Infectious Diseases 2009, 9:92 http://www.biomedcentral.com/1471-2334/9/92
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prevalence and lower MDA coverage to Samoa and Cook
Islands post-MDA prevalence is not known.
Vanuatu's primary LF vector is an Anopheles sp., which is
also responsible for the transmission of malaria. Vanuatu
has been implementing a treated bed-net programme
since 1988. Models theorise that adding vector control to
MDA campaigns will decrease the number of years
required to meet the target prevalence, for a given baseline
endemicity [11]. Again, the contribution of an Anopheles
vector and a treated bed-net programme on the post-MDA
prevalence of 0.2% in Vanuatu after five MDAs is not
known.
Unfortunately, a lack of data precludes conclusions being
drawn about which factors influenced the apparent
decrease in prevalence for these countries and the degree
to which MDA was associated with a decrease. Most coun-
tries used non-standardised methods, with different sam-
ple sizes and convenience sampling to establish their
prevalence at the start of the programme. While this is
understandable due to logistic issues that are common in
developing countries [13], it limits comparisons between
initial and post-MDA LF antigenaemia prevalence except
in Niue where the entire available population was
included in each survey.
The Pacific Programme to Eliminate Lymphatic Filariasis'
strategy called for five rounds of MDA followed by a prev-
alence survey to assess the impact. Unlike the global pro-
gramme, which aimed for ≥80% coverage of the "at risk"
population, no specific target was set for the level of cov-
erage to be reached at a national level within each country.
Similarly, a coverage survey was not carried out to assess
the true coverage achieved. It is likely that higher MDA
coverage has contributed to the low prevalence measured
in the countries that achieved the programme target.
However, it is unfortunate that data limitations preclude
exploration of the relationship between coverage levels
and program performance. Inaccurate denominator pop-
ulation statistics are common in the Pacific and other
regions in the world where LF programmes are underway
or planned. Therefore, an independent means of assessing
MDA coverage should be considered.
Even if true denominator data was available for each
country for every year, estimates of MDA coverage should
be viewed with some caution, as it may only reflect drug
distribution, rather than drug consumption. A study from
India reported that up to 25% of people who received
medications during an MDA did not actually take them
[14]. Anecdotal reports to the WHO advised that the
majority of Pacific MDAs were not "directly observed ther-
apy", and as such, it is unknown whether all drugs were
consumed. Directly observed therapy is highly recom-
mended for LF programmes as it may increase compliance
with drug administration and allow a more accurate esti-
mate of MDA coverage.
Community members who do not participate in MDA
may serve as reservoirs of LF infection [15] and it has been
recommended that social research approaches should be
used to explore barriers to MDA compliance [16,17]. One
of the recommendations of the Pacific Programme to
Eliminate Lymphatic Filariasis is that if countries do not
reach the post-MDA survey goal of <1% antigenaemia, tar-
geted MDA and vector control should be considered.
Clearly administration of targeted MDA will require the
identification of groups that do not participate in the
MDA and a recommendation of a minimum coverage to
be reached. The use of appropriate social science methods
in conjunction with a representative MDA coverage sur-
vey, could independently measure MDA coverage as well
as uncover attitudes, behaviours or beliefs that may
impact on the success of future LF elimination efforts.
Coverage surveys should also determine what proportion
of doses was actually administered under direct observa-
tion.
Conclusion
It is encouraging to observe that countries in the Pacific
Programme to Eliminate Lymphatic Filariasis are achiev-
ing their LF elimination targets. Niue, Tonga and Vanuatu
have all achieved the target of an LF antigenaemia preva-
lence of <1%, following five rounds of MDA. Although
four to six rounds of MDA appear to diminish antigenae-
mia prevalence, essential for interrupting LF transmission,
it is likely that baseline prevalence, MDA coverage and the
presence of an efficient vector, such as Aedes polynesiensis,
are important determinants of post-MDA outcome. This
case study from the Pacific highlights the importance of
collecting valid and representative data before initiating
and during the delivery of public health programmes to
learn about the factors that inhibit or promote target
attainment.
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